Abbott India Ltd vs Jagsonpal Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Abbott India Ltd is ₹ 26898 as of 12 May 15:30 . The P/E Ratio of Abbott India Ltd changed from 46.1 on March 2021 to 46.2 on March 2025 . This represents a CAGR of 0.04% over 5 yearsThe P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 years The Market Cap of Abbott India Ltd changed from ₹ 31850 crore on March 2021 to ₹ 65302 crore on March 2025 . This represents a CAGR of 15.44% over 5 yearsThe Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 years The revenue of Abbott India Ltd for the Mar '26 is ₹ 1785 crore as compare to the Dec '25 revenue of ₹ 1793 crore. This represent the decline of -0.49% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The ebitda of Abbott India Ltd for the Mar '26 is ₹ 556.44 crore as compare to the Dec '25 ebitda of ₹ 533.23 crore. This represent the growth of 4.35% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The net profit of Abbott India Ltd changed from ₹ 328.01 crore to ₹ 394.93 crore over 8 quarters. This represents a CAGR of 9.73% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The Dividend Payout of Abbott India Ltd changed from 84.61 % on March 2021 to 71.36 % on March 2025 . This represents a CAGR of -3.35% over 5 yearsThe Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 years .

About Abbott India Ltd

Abbott India Ltd Share Price Overview Abbott India Ltd share price history records the movement of the stock in various phases of the market.
Company developments, as well as the general trends in the pharmaceutical industry, have influenced this movement.
As a healthcare-oriented company, the stock tends to respond to fluctuations in the demand of drugs, regulatory activities, and the general mood of investors.
The past performance of the stock gives the investors an idea of how it has reacted to the change in earnings, product portfolio development, and significant company occurrences at various times. Long-Term Performance The stock price performance of Abbott India Ltd has seen phases of fluctuation over time, with a 18% CAGR over the last 10 years.
This reflects movement across different market conditions, with periods of strength and correction.

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

FAQs for the comparison of Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd

Which company has a larger market capitalization, Abbott India Ltd or Jagsonpal Pharmaceuticals Ltd?

Market cap of Abbott India Ltd is 57,158 Cr while Market cap of Jagsonpal Pharmaceuticals Ltd is 1,427 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd?

The stock performance of Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd?

As of May 12, 2026, the Abbott India Ltd stock price is INR ₹26898.1. On the other hand, Jagsonpal Pharmaceuticals Ltd stock price is INR ₹212.65.

How do dividend payouts of Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Jagsonpal Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.